The expected therapeutic effect of estrogen as an adjunct treatment to antipsychotics in women suffering from schizophrenia for relapse prevention was to be tested under real-life conditions. A multicenter, randomized, placebo-controlled, double-blind, cross-over study based on an A-B-A-B (and/or B-A-B-A) design was applied. Forty-six hypoestrogenic women with schizophrenia hospitalized for the first time or repeatedly were included in the study. Their average age was 37.9 and they had been suffering from schizophrenia for 8.4 years. During the drug treatment phases, they received a three-phase estrogen-gestagen combination drug (17beta-estradiol+norethisterone acetate) in addition to an antipsychotic drug. Significant effects of the adjuvant hormone replacement therapy on the estradiol levels could be observed, and high and low levels of estradiol prevailed in the active drug and placebo phases, respectively. We did not find any difference either in defined relapse events or in the psychopathology between estradiol replacement and placebo phases. Neither did the required antipsychotic doses or the tolerance data differ between the two phases. Thus, the results of our study do not confirm the hypothesis that a combined estradiol/antipsychotic therapy is superior to an antipsychotic monotherapy for relapse prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.schres.2004.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patients with severe mental illness in the general emergency department: Clinical characteristics, quality of care and challenges.
Gen Hosp Psychiatry
December 2024
Geha Mental Health Center, Petach Tikva, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Background: Morbidity and mortality rates are notably higher among individuals with severe mental illnesses (SMI). People with SMI often have lower access to healthcare services, and the medical care they receive is known to be suboptimal. Consequently, treatment in an acute care setting rather than a community setting is more common.
View Article and Find Full Text PDFInitiation of Psychotropic Drugs in Spouses of Patients With Early-Onset Alzheimer's Disease: A Matched Cohort Study.
Int J Geriatr Psychiatry
January 2025
Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
Objectives: The diagnosis of early-onset Alzheimer's disease (EOAD) can cause emotional stress not only to the patients themselves but also to their spouses. This study aimed to evaluate the risk of psychiatric disorders in spouses of EOAD patients, using psychotropic drug initiation as a surrogate indicator.
Methods: A cohort study was conducted using a Japanese claims database, with spouses of EOAD patients (exposed spouses) matched with spouses of non-EOAD individuals (reference spouses) up to a 1:10 ratio.
Introduction: This study aimed to evaluate the predictive validity and discriminatory ability of clinical outcomes, inflammatory activity, oxidative and vascular damage, and metabolic mechanisms for detecting significant improve maximum heart rate after physical activity training in individuals with psychiatric disorders and obesity comorbid using a longitudinal design and transdiagnostic perspective.
Methods: Patients with major depressive disorder, bipolar disorder and, schizophrenia and with comorbid obesity (n = 29) were assigned to a 12-week structured physical exercise program. Peripheral blood biomarkers of inflammation, oxidative stress, vascular mechanisms, and metabolic activity, as well as neurocognitive and functional performance were assessed twice, before and after intervention.
Basic Science and Pathogenesis.
Alzheimers Dement
December 2024
G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Background: Neuropsychiatric Symptoms (NPS) (e.g., aggression, psychosis, anxiety, apathy, depression, agitation, sleep disturbances, repetitive behaviors) occur in 85% of AD patients, and are associated with accelerated decline, out-of-home placement, increased costs, and greatly increased suffering of patients and families.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
Background: First-degree relatives of patients suffering from Alzheimer's Dementia (AD) are at increased risk for developing dementia, yet the associations between family history of AD and cognitive dysfunction remain unclear. Our study aims to understand the intricate interplay between familial risk factors and neurocognitive functioning in AD FDRs versus FDRs of other major psychiatric illnesses by comparing the neuro- cognitive functions of unaffected first-degree relatives (FDR) of patients with AD with unaffected FDR of other major psychiatric illness including Schizophrenia(SCHIZ), Substance use disorders(SUD), Obsessive compulsive disorders(OCD) and Bipolar disorder(BPAD). Subsequently, we also compare the Neuro cognitive performance of FDR's of AD at baseline and after two years longitudinally.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!